Amalgamated Bank Has $1.39 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Amalgamated Bank grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 937.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,577 shares of the company's stock after acquiring an additional 6,847 shares during the quarter. Amalgamated Bank's holdings in Krystal Biotech were worth $1,391,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Jamison Private Wealth Management Inc. acquired a new stake in shares of Krystal Biotech during the second quarter worth about $28,000. GAMMA Investing LLC grew its holdings in shares of Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after acquiring an additional 93 shares in the last quarter. Key Financial Inc bought a new position in Krystal Biotech in the second quarter valued at approximately $28,000. Blue Trust Inc. increased its holdings in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock worth $30,000 after buying an additional 163 shares during the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Krystal Biotech during the 2nd quarter worth about $71,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company's stock, valued at $296,814,424.32. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 14.10% of the company's stock.

Wall Street Analyst Weigh In

KRYS has been the subject of a number of research analyst reports. Chardan Capital boosted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a report on Monday, August 5th. HC Wainwright raised their target price on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a "buy" rating in a report on Wednesday, August 28th. Evercore ISI boosted their price target on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research note on Monday, August 12th. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and an average target price of $196.75.

Krystal Biotech Trading Down 0.6 %

Shares of Krystal Biotech stock opened at $178.41 on Friday. Krystal Biotech, Inc. has a 1 year low of $93.95 and a 1 year high of $219.34. The firm has a market capitalization of $5.10 billion, a PE ratio of 95.41 and a beta of 0.82. The firm's 50 day moving average is $193.45 and its 200 day moving average is $179.60.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm's revenue was up 70283900.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.25) earnings per share. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).